Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2009 4
2010 3
2012 3
2013 2
2014 3
2015 1
2016 3
2019 1
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

24 results
Results by year
Filters applied: . Clear all
Page 1
NK cells for cancer immunotherapy
Shimasaki N, et al. Nat Rev Drug Discov 2020 - Review. Among authors: Campana D. PMID 31907401
Natural killer (NK) cells can swiftly kill multiple adjacent cells if these show surface markers associated with oncogenic transformation. ...
Natural killer (NK) cells can swiftly kill multiple adjacent cells if these show surface markers associated with oncogenic tra
Engineering of Natural Killer Cells for Clinical Application.
Shimasaki N and Campana D. Methods Mol Biol 2020. PMID 31776921
It has been known for nearly half a century that a subset of lymphocytes called natural killer (NK) cells can recognize and kill cancer cells, but their clinical potential as therapeutics has not yet been fully explored. ...
It has been known for nearly half a century that a subset of lymphocytes called natural killer (NK) cells can recognize and ki …
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Kamiya T, et al. J Clin Invest 2019. Among authors: Campana D. PMID 30860984 Free PMC article.
A key mechanism of tumor resistance to immune cells is mediated by expression of peptide-loaded HLA-E in tumor cells, which suppresses natural killer (NK) cell activity via ligation of the NK inhibitory receptor CD94/NKG2A. ...
A key mechanism of tumor resistance to immune cells is mediated by expression of peptide-loaded HLA-E in tumor cells, which suppresses na
Expanded and armed natural killer cells for cancer treatment.
Shimasaki N, et al. Cytotherapy 2016 - Review. Among authors: Campana D. PMID 27497701
The capacity of natural killer (NK) cells to recognize and kill transformed cells suggests that their infusion could be used to treat cancer. ...Thus, expanded NK cells can be armed with activating receptors that enhance their natural anti-tumor capacity or with chimeric antigen receptors that can redirect them towards specific tumor targets. ...
The capacity of natural killer (NK) cells to recognize and kill transformed cells suggests that their infusion could be used t …
Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.
Wang W, et al. Cancer Immunol Immunother 2016. Among authors: Campana D. PMID 27392940 Free PMC article.
Interactions between killer immunoglobulin-like receptors (KIR) on human NK cells and KIR-ligands on tumor cells influence the magnitude of NK function. ...
Interactions between killer immunoglobulin-like receptors (KIR) on human NK cells and KIR-ligands on tumor cells influence the magnit …
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T, et al. Cancer Immunol Res 2016. Among authors: Campana D. PMID 27197065 Free article.
Natural killer (NK) cells recognize virally infected and oncogenically transformed cells, suggesting a therapeutic role for NK-cell infusions in HCC. ...
Natural killer (NK) cells recognize virally infected and oncogenically transformed cells, suggesting a therapeutic role for NK
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Szmania S, et al. J Immunother 2015 - Clinical Trial. Among authors: Campana D. PMID 25415285 Free PMC article.
Highly activated/expanded natural killer (NK) cells can be generated by stimulation with the human leukocyte antigen-deficient cell line K562, genetically modified to express 41BB-ligand and membrane-bound interleukin (IL)15. ...
Highly activated/expanded natural killer (NK) cells can be generated by stimulation with the human leukocyte antigen-deficient …
Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M, et al. Blood 2014. Among authors: Campana D. PMID 25006133
Natural killer (NK) cell survival and, hence, cytotoxicity requires cytokine support. We determined whether expression of interleukin-15 (IL-15) in a nonsecretory, membrane-bound form could sustain NK cell growth. ...
Natural killer (NK) cell survival and, hence, cytotoxicity requires cytokine support. We determined whether expression of inte
4-1BB chimeric antigen receptors
Campana D, et al. Cancer J 2014 - Review. PMID 24667959
Among these, those mediated by 4-1BB (CD137, TNFRSF9) are critical for tumor immunity. 4-1BB is expressed in T-cell receptor-activated lymphocytes as well as natural killer cells and other hematopoietic and nonhematopoietic cells. 4-1BB ligation induces a signaling cascade that results in cytokine production, expression of antiapoptotic molecules, and enhanced immune responses. ...In this review, we discuss the properties of 4-1BB, the design of 4-1BB CARs, and the function of T lymphocytes and natural killer cells expressing them....
Among these, those mediated by 4-1BB (CD137, TNFRSF9) are critical for tumor immunity. 4-1BB is expressed in T-cell receptor-activated lymph …
Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer.
Mimura K, et al. Int J Cancer 2014. Among authors: Campana D. PMID 24615495 Free article.
To develop more effective therapies for patients with advanced gastric cancer, we examined the potential of ex vivo expanded natural killer (NK) cells. ...
To develop more effective therapies for patients with advanced gastric cancer, we examined the potential of ex vivo expanded natural
24 results
Jump to page
Feedback